Uterus1.com: Great Information, Real Community, Better Living.
 Main Page
 Uterus News
Feature Story
 Education Center


Find a Physician
HTA in the News
 Heavy Periods Center
sharonbober  Uterus

Dr. Sharon Bober:
Healing the Sex Lives of Cancer Patients
About Heroes
 Join the Discussion in  Our Forums
Uterus1 Forums
Patient Stories
    Asked Questions

One Question Poll

Locate a Specialist
Online Resources
Uterus Anatomy
Video Library
Menstrual Diary
Office Visits
Patient Brochures
Search the Body1 Network
July 13, 2020  
UTERINE NEWS: Feature Story

  • Print this Article
  • Email this Article
  • Examining the Effects of MS Drugs on Pregnancy

    New Research Examines Effects of MS Drugs on Pregnancy

    February 06, 2006

    By: Diana Barnes-Brown for Uterus1

    Take Action
    If you are a woman receiving interferon beta1-A or beta1-B drug therapies for MS, and if you are considering becoming pregnant, here are some important questions to consider with your doctor or healthcare specialist before making the decision to conceive or to continue or stop drug therapy:

  • Given the progression of the disease, what are the pros and cons of continuing drug treatment? What improvements in my condition or other benefits have we noticed in my case? What about negative effects?

  • Given the progression of the disease, what are the pros and cons of stopping drug treatment to become pregnant? Is a relapse likely for me?

  • What form of MS do I have, and are there any specific drawbacks to stopping drug therapy with my form of MS? (There are four forms, also known as clinical courses, of MS: Relapsing-Remitting, Primary-Progressive, Secondary-Progressive, and Progressive-Relapsing)

  • If I do choose to stop drug therapy while pregnant and breastfeeding, what potential symptoms or signs of danger to myself or my pregnancy should I be aware of?

  • After reviewing these questions, what is the best decision for my health and for the health of my future pregnancy? Am I comfortable with the risks, or would I prefer to become a parent in another way, such as by adoption or with the help of a surrogate mother?

  • For those stricken by Multiple Sclerosis (MS), drug therapies using interferion drugs such as interferon beta-1a and interferon beta-1b (marketed under the brand names Avonex, Rebif, and Betaferon) can make a huge difference in the rate and severity of the disease’s progression. But, until recently, women were advised to refrain from taking MS drugs while pregnant, because the effects of the drugs on women and their developing pregnancies were not known.

    Women who became pregnant while taking the drugs often felt abortion was the best option to prevent the potential for devastating birth defects or other problems often connected to potent drug therapies administered during pregnancy.

    But two studies published in 2005 offered a first glimpse into whether risks to mother and baby actually exist, and what those risks might be.

    One study examined the data for 69 women who were involved in trials for interferon beta-1a or 1b and became pregnant at some point during the trial period. Of the 69 women, 41 were receiving the drug therapy when they became pregnant and 22 had stopped receiving active therapy before becoming pregnant. A total of 20 women in each group carried the pregnancies to full term and had healthy, live births.

    Nine women in the group receiving active drug therapy at conception suffered miscarriages, while the remaining women chose to have abortions.

    In the second study, 64 pregnancies, 24 of which occurred during interferon drug therapy, were examined by researchers at the Hospital for Sick Children at the University of Toronto. The group, led by Dr. Gideon Koren, director of the hospital’s Motherisk Program, found that 55 percent of the women receiving interferon therapy had healthy pregnancies, compared to 81 percent who stopped taking the drugs. The remainder of the pregnancies resulted in miscarriage.

    Because both the studies were fairly small in scale, it is hard to determine whether the results are representative for all women, or potentially due to other co-factors. Also, since MS affects many parts and functions of the body, it was unclear whether the disease or the treatment may have been at the root of pregnancies that were not successful.

    Further, forgoing treatment during pregnancy can have consequences for expecting mothers: Studies on MS and pregnancy have shown that there is a higher risk of relapse or periods of degeneration after pregnancy, and keeping up with treatment regimens may help to prevent such relapses. The effects of MS drugs on MS itself during pregnancy has yet to be studied, but part of why the drugs work when they do is that they can forestall destructive relapse periods, preserving the brain and other affected structures for as long as possible, rather than repairing damage after it occurs.

    While the results were not conclusive, they represent an important step forward in MS care. Women compose two-thirds of all MS patients, and most are diagnosed during the childbearing years.

    Last updated: 06-Feb-06

    Interact on Uterus1

    Discuss this topic with others.
    Feature Archives

    Breast Milk as Nutrition and Medication for Critically Ill Infants

    Study Finds New Moms Still Excessively Sleepy After Four Months

    Preterm Infants and Their Mothers Benefit from Maternal Singing During Skin-to-Skin Contact

    Stress Impacts Ability to Get Pregnant

    Link Discovered Between Bacteria and Premature Water Breaking

    Next 5 Features ...

    More Features ...
    Related Multimedia

    Interview with James Spies, M.D. about Treatments for Fibroids

    Dr. Schneller Interview Question: Are most of your patients long term patients?

    Dr. Schneller Question: What drew you to rheumatology?

    More Features ...
    Related Content
    Cancer and Pregnancy: New Hope for Some Expectant Mothers

    Pregnancy with Fibroids: What Are the Risks?

    In Vitro Fertilization (IVF) Success Rates Vary By Race

    Birth Rates On the Rise in Older Women

    New Guidelines Assess Pregnancy and Asthma

    More Features ...
    Home About Us Press Jobs Advertise With Us Contact Us
    © 2020 Body1 All rights reserved.
    Disclaimer: The information provided within this website is for educational purposes only and is not a substitute for consultation with your physician or healthcare provider. The opinions expressed herein are not necessarily those of the Owners and Sponsors of this site. By using this site you agree to indemnify, and hold the Owners and Sponsors harmless, from any disputes arising from content posted here-in.